November 13, 2007 — Arterial Remodeling Technologies (ART) will receive $7.8 million from investors to pursue CE Mark clearance for a bioresorbable stent that reportedly dismantles in vivo over a specific time horizon.
The stents are designed to be both hemocompatible and biocompatible, to reduce thrombus or inflammation, while disappearing over time.
